171 related articles for article (PubMed ID: 22437411)
1. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial.
Coyne DW
Kidney Int; 2012 Jul; 82(2):235-41. PubMed ID: 22437411
[TBL] [Abstract][Full Text] [Related]
2. Are there implications from the Trial to Reduce Cardiovascular Events with Aranesp Therapy study for anemia management in dialysis patients?
Berns JS
Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):567-72. PubMed ID: 20601876
[TBL] [Abstract][Full Text] [Related]
3. The normal HCT trial re-revisited: what were the actual findings?
Besarab A; Bolton WK; Nissenson AR; Schwab SJ
Kidney Int; 2012 Jul; 82(2):242; author reply 242-3. PubMed ID: 22743566
[No Abstract] [Full Text] [Related]
4. The impact of hyporesponsiveness to erythropoietin-stimulating agents on time-dependent mortality risk among CKD stage 5D patients: a single-center cohort study.
Ishigami J; Onishi T; Shikuma S; Akita W; Mori Y; Asai T; Kuwahara M; Sasaki S; Tsukamoto Y
Clin Exp Nephrol; 2013 Feb; 17(1):106-14. PubMed ID: 22752396
[TBL] [Abstract][Full Text] [Related]
5. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients.
Kilpatrick RD; Critchlow CW; Fishbane S; Besarab A; Stehman-Breen C; Krishnan M; Bradbury BD
Clin J Am Soc Nephrol; 2008 Jul; 3(4):1077-83. PubMed ID: 18417744
[TBL] [Abstract][Full Text] [Related]
6. It's time to compare anemia management strategies in hemodialysis.
Coyne DW
Clin J Am Soc Nephrol; 2010 Apr; 5(4):740-2. PubMed ID: 20299363
[TBL] [Abstract][Full Text] [Related]
7. A physician's perseverance uncovers problems in a key nephrology study.
Fishbane S; Wish JB
Kidney Int; 2012 Jul; 82(2):135-7. PubMed ID: 22743565
[TBL] [Abstract][Full Text] [Related]
8. Should asymptomatic patients discharged with lower hemoglobin expect worse outcomes after valve surgery?
Ad N; Holmes SD; Shuman DJ; Speir AM; Pritchard G; Halpin L
J Thorac Cardiovasc Surg; 2015 Nov; 150(5):1322-8. PubMed ID: 26318009
[TBL] [Abstract][Full Text] [Related]
9. Association between responsiveness to methoxy polyethylene glycol-epoetin beta and renal survival in patients with non-dialysis-dependent chronic kidney disease: A pooled analysis of individual patient-level data from clinical trials.
Tsuruya K; Uemura Y; Hirakata H; Kitazono T; Tsubakihara Y; Suzuki M; Ohashi Y
Nephrology (Carlton); 2017 Oct; 22(10):769-775. PubMed ID: 27312361
[TBL] [Abstract][Full Text] [Related]
10. Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL.
Bradbury BD; Danese MD; Gleeson M; Critchlow CW
Clin J Am Soc Nephrol; 2009 Mar; 4(3):630-7. PubMed ID: 19261826
[TBL] [Abstract][Full Text] [Related]
11. Treating Posttransplant Anemia With Erythropoietin Improves Quality of Life but Does Not Affect Progression of Chronic Kidney Disease.
Pile T; Raftery M; Thuraisingham R; Kirwan CJ; Harwood S; Yaqoob MM
Exp Clin Transplant; 2020 Feb; 18(1):27-33. PubMed ID: 31180297
[TBL] [Abstract][Full Text] [Related]
12. Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol.
Strippoli GF;
Trials; 2010 Jun; 11():70. PubMed ID: 20534124
[TBL] [Abstract][Full Text] [Related]
13. Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study.
Heinze G; Kainz A; Hörl WH; Oberbauer R
BMJ; 2009 Oct; 339():b4018. PubMed ID: 19854839
[TBL] [Abstract][Full Text] [Related]
14. Tips for erythropoiesis-stimulating agent treatment of renal anemia.
Tomosugi N; Koshino Y
Clin Exp Nephrol; 2020 Jan; 24(1):105-106. PubMed ID: 31617026
[No Abstract] [Full Text] [Related]
15. Association of hemoglobin variability and mortality among contemporary incident hemodialysis patients.
Brunelli SM; Lynch KE; Ankers ED; Joffe MM; Yang W; Thadhani RI; Feldman HI
Clin J Am Soc Nephrol; 2008 Nov; 3(6):1733-40. PubMed ID: 18922985
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietic stimulating agents and quality of a patient's life: individualizing anemia treatment.
Kliger AS; Fishbane S; Finkelstein FO
Clin J Am Soc Nephrol; 2012 Feb; 7(2):354-7. PubMed ID: 22266571
[TBL] [Abstract][Full Text] [Related]
17. Individualizing decision-making--resurrecting the doctor-patient relationship in the anemia debate.
Agarwal R
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1340-6. PubMed ID: 20448071
[TBL] [Abstract][Full Text] [Related]
18. Combination of maintenance hemodialysis with hemoperfusion: a safe and effective model of artificial kidney.
Chen SJ; Jiang GR; Shan JP; Lu W; Huang HD; Ji G; Wu P; Wu GF; Wang W; Zhu C; Bian F
Int J Artif Organs; 2011 Apr; 34(4):339-47. PubMed ID: 21534244
[TBL] [Abstract][Full Text] [Related]
19. Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL.
Bradbury BD; Do TP; Winkelmayer WC; Critchlow CW; Brookhart MA
Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):932-40. PubMed ID: 19572312
[TBL] [Abstract][Full Text] [Related]
20. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.
Wright JR; Ung YC; Julian JA; Pritchard KI; Whelan TJ; Smith C; Szechtman B; Roa W; Mulroy L; Rudinskas L; Gagnon B; Okawara GS; Levine MN
J Clin Oncol; 2007 Mar; 25(9):1027-32. PubMed ID: 17312332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
